Le Lézard
Classified in: Health, Science and technology
Subject: OFR

Poseida Therapeutics Announces Pricing of Initial Public Offering


SAN DIEGO, July 9, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced the pricing of its initial public offering of 14,000,000 shares of its common stock at a price to the public of $16.00 per share. The gross proceeds to Poseida from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $224.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on July 10, 2020 under the symbol "PSTX". The offering is expected to close on July 14, 2020, subject to satisfaction of customary closing conditions. In addition, Poseida has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock at the initial public offering price less underwriting discounts and commissions.

BofA Securities, Piper Sandler and William Blair are acting as joint book-running managers for the offering.

The offering is being made only by means of a prospectus. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on July 9, 2020.  The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, from: BofA Securities, Inc., NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at prospectus@psc.com; or William Blair & Company, L.L.C., 150 North Riverside Plaza, Chicago, IL 60606, Attention: Prospectus Department, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Poseida Therapeutics, Inc.

Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Modification System, Cas-CLOVERtm site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics.

SOURCE Poseida Therapeutics, Inc.


These press releases may also interest you

at 16:10
AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020. AgeX made strides with...

at 16:10
Scottsdale Arizona science professor and parent, Dr. Libby Hart-Wells, qualified for the 2020 ballot to run for a Scottsdale Unified School District governing board position in November. "I am honored and grateful to be on the ballot for the SUSD...

at 16:05
Neptune Wellness Solutions Inc. ("Neptune" or the "Company") , a diversified and fully integrated health and wellness company focused on plant-based, sustainable and purpose-driven lifestyle brands, announced  the voting results for the matters...

at 16:05
ThermoGenesis Holdings, Inc. , a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced financial and operating results for the second quarter ended June 30, 2020 and provided a corporate...

at 16:00
Inc. magazine today revealed that Universal Processing is No. 4750 on its annual Inc. 5000 list, the most prestigious ranking of the nation's fastest-growing private companies. The list represents a unique look at the most successful companies within...

at 15:57
Lancium LLC, the leader in data center power ramping software, today filed a lawsuit alleging patent infringement against Layer1 Technologies, Inc. in the Western District of Texas....



News published on 9 july 2020 at 19:13 and distributed by: